Compare Merck & Co., Inc. (MRK) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs New York Times Co — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while New York Times Co trades at $66.8 (market cap $10.96B). The key difference: Merck & Co., Inc. is far larger — about 33.4× New York Times Co's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | NYT | |
|---|---|---|
Market Cap | $366.28B | $10.96B |
Sector | Health | Media |
52-Week High | $156.43 | $85.86 |
52-Week Low | $77.60 | $54.66 |
Enterprise Value | $413.04B | $10.36B |
Dividend Yield | 2.29% | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal and mixed moving averages. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.69 exceeding the $0.663 forecast. Revenue growth is steady, rising from $2.3B in 2022 to $2.8B in 2025, with net profit margins improving to 12.17%. The company maintains strong cash flow from operations at $584.49M in 2025. Analyst consensus is a $76.00 price target, though the majority recommend Hold.
Outlook remains cautiously optimistic given earnings momentum and solid fundamentals, but risks include the ongoing OpenAI copyright lawsuit and competitive pressures in digital media. The stock offers potential upside to the consensus target, supported by institutional buying interest, though sentiment is tempered by regulatory and litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
